In contrast, reduced expression of AR in CAFs, often in response to androgen/AR-pathway directed therapies, appears to promote tumor growth and progression, correlating with a high Gleason score, disease recurrence, and shorter progression-free survival [258,265,266,267]. This evidence concerns the gene AR and neoplasm.